Citigroup Inc Infla Rx N.V. Transaction History
Citigroup Inc
- $190 Billion
- Q1 2025
A detailed history of Citigroup Inc transactions in Infla Rx N.V. stock. As of the latest transaction made, Citigroup Inc holds 1,301 shares of IFRX stock, worth $1,053. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,301
Previous 1,301
-0.0%
Holding current value
$1,053
Previous $3,000
66.67%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding IFRX
# of Institutions
36Shares Held
18.2MCall Options Held
33.6KPut Options Held
2.2K-
Suvretta Capital Management, LLC New York, NY6.48MShares$5.25 Million0.29% of portfolio
-
683 Capital Management, LLC New York, NY2.63MShares$2.13 Million0.22% of portfolio
-
Eversept Partners, LP New York, NY1.68MShares$1.36 Million0.19% of portfolio
-
Morgan Stanley New York, NY1.26MShares$1.02 Million0.0% of portfolio
-
Silverarc Capital Management, LLC1.16MShares$940,8690.29% of portfolio
About InflaRx N.V.
- Ticker IFRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 44,203,800
- Market Cap $35.8M
- Description
- InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a nov...